Moving Forward in Cervical Cancer: Enhancing Susceptibility to DNA Repair Inhibition and Damage, an NCI Clinical Trials Planning Meeting Report

Author:

Harkenrider Matthew M1,Markham Merry Jennifer2ORCID,Dizon Don S3ORCID,Jhingran Anuja4,Salani Ritu5,Serour Ramy K6ORCID,Lynn Jean7ORCID,Kohn Elise C8

Affiliation:

1. Department of Radiation Oncology, Stritch School of Medicine, Loyola University Chicago, Chicago, IL, USA

2. Division of Hematology and Oncology, University of Florida College of Medicine, Gainesville, FL, USA

3. Division of Hematology and Oncology, Department of Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA

4. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

5. The Ohio State University Wexner Medical Center, Columbus, OH, USA

6. The Emmes Company, LLC, Rockville, MD, USA

7. Coordinating Center for Clinical Trials, National Cancer Institute, Bethesda, MD, USA

8. Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA

Abstract

Abstract Cervical cancer is the fourth most common cancer in women worldwide, and prognosis is poor for those who experience recurrence or develop metastatic disease, in part due to the lack of active therapeutic directions. The National Cancer Institute convened a Cervical Cancer Clinical Trials Planning Meeting in October 2018 to facilitate the design of hypothesis-driven clinical trials focusing on locally advanced, metastatic, and recurrent cervical cancer around the theme of enhancing susceptibility to DNA repair inhibition and DNA damage. Before the meeting, a group of experts in the field summarized available preclinical and clinical data to identify potentially active inducers and inhibitors of DNA. The goals of the Clinical Trials Planning Meeting focused on identification of novel experimental strategies capitalizing on DNA damage and repair (DDR) regulators and cell cycle aberrations, optimization of radiotherapy as a DDR agent, and design of clinical trials incorporating DDR regulation into the primary and recurrent or metastatic therapies for cervical carcinoma. Meeting deliverables were novel clinical trial concepts to move into the National Clinical Trials Network. This report provides an overview for the rationale of this meeting and the state of the science related to DDR regulation in cervical cancer.

Funder

NCI Coordinating Center for Clinical Trials

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Reference79 articles.

1. Cancer statistics, 2019;Siegel;CA A Cancer J Clin,2019

2. Integrated genomic and molecular characterization of cervical cancer;Burk;Nature,2017

3. Cancer of the cervix uteri;Bhatla;Int J Gynecol Obstet,2018

Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3